Nanalysis Scientific (NSCI) Q3 2024 earnings summary

Executive summary

• Achieved 50% year-over-year revenue growth in Q3 2024, reaching CAD 10.6 million ($10.6 million), with significant margin improvements and positive adjusted EBITDA, reflecting strong execution in both product and service segments.

• Net loss narrowed to CAD 1.6 million ($1,644K) from CAD 6.3 million ($6,287K) in the prior year, reflecting improved operational efficiency and cost reductions.

• Margin expansion in both business segments, with product sales gross margin at 52% and security services at 15%.

• Positive adjusted EBITDA of CAD 264,000 ($264K) in Q3 2024, a significant turnaround from a loss of CAD 1.4 million ($1,354K) in Q3 2023.

• Completed a large medical imaging hardware sale, offsetting typical seasonal slowdown in Benchtop NMR.

Financial highlights

• Q3 2024 consolidated revenue was CAD 10.6 million ($10,570K), up 50% from Q3 2023.

• Product sales reached CAD 4.2 million ($4,242K) and security service revenue CAD 5.4 million ($5,420K) in Q3 2024.

• Adjusted EBITDA improved by CAD 1.6 million ($1,618K) year-over-year to CAD 264,000 ($264K).

• Net loss reduced by CAD 4.6 million ($4,643K) year-over-year, with prior year including a CAD 2.8 million ($2.8M) one-time charge.

• Cash on hand was CAD 223,000, with an undrawn credit facility of CAD 2.1 million and working capital of CAD 4 million at quarter-end.

Outlook and guidance

• Q4 is expected to be the strongest quarter, with CAD 600,000 in orders deferred from Q3 and historical trends supporting a strong finish.

• Expects continued strong sales and further margin expansion in Q4 2024 and into 2025, with new product launches including next-generation Benchtop NMR platforms.

• Service contract margins expected to grow through 2024 and 2025 as efficiencies increase.

• Plans to focus more on proprietary products and services, reducing third-party product sales.

• Management remains focused on operational improvements to achieve profitability.